Electronic product information: from principles to actions. AESGP, EFPIA and Medicines for Europe reflections on EMAHMA – EC Key principles for electronic product information
The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days
Biosimilar medicines are available in therapy areas which represent 65% of the biologics market by value
In Europe, biosimilar medicines have captured 7% more of the biologics market over a 5-year period
Growing number of biologic therapies offers future opportunities for biosimilar development
In Bavaria, biosimilar competition led to rheumatic patients receive faster access to biological therapy
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
